Skip to main content
56th ASAM Annual Conference Main banner
Final Program


Preview Program
Back

Collaborative Session

Concurrent Sessions #4

NIH HEAL Initiative: Results from Selected NIDA Clinical Trials Network Studies

Friday, April 25, 2025
3:00 PM – 4:15 PM  
This session will provide results from three large multi-site trials conducted in the CTN funded by the HEAL Initiative: The feasibility of a 7-day injectable XR-buprenorphine in ED settings for those who present with minimal to mild opioid withdrawal symptoms: The successful initiation of XR-naltrexone for OUD using a rapid procedure in hospitalized patients ; and A collaborative care model for adult primary care patients with risky opioid use in preventing progression to moderate or severe OUD.

Learning Objectives:

Learners will be able to:
  • Upon completion the participant will be able to identify patients with OUD eligible for 7-day extended release buprenorphine and discuss advantages for use.
  • Upon completion, the participant will be able to describe the rapid procedure for extended release naltrexone including implications to be learned from the implementation of the procedure in the CTN-0097 trial
  • Upon completion, participants will be able to describe the elements of a collaborative care model for patients with subthreshold opioid use disorder, and understand about managing patients with risky opioid use in primary care
Disclosure(s):
Geetha A. Subramaniam, MD, DLFAPA, DFAACAP: No financial relationships to disclose
Jennifer McNeely, MD, MS: No financial relationships to disclose
Kathryn F. Hawk, MD, MHS: No financial relationships to disclose
Adam M. Bisaga, MD: No disclosure to display